Assessment of Herb-Drug Interaction Potential of Five Common Species of Licorice and Their Phytochemical Constituents

References

• Valli G, Giardina E-GV. Benefits, adverse effects and drug interactionsof herbal therapies with cardiovascular effects. J Am Coll Cardiol. 2002;39(7):1083–95. doi:10.1016/S0735-1097(02)01749-7.
   PubMed Web of Science ®Google Scholar
• Sun H-X, Pan H-J. Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice. Vaccine. 2006;24(11):1914–20. doi:10.1016/j.vaccine.2005.10.040.
   PubMed Web of Science ®Google Scholar
• Yang R, Wang L-q, Yuan B-c, Liu Y. The pharmacological activities of licorice. Planta Med. 2015;81(18):1654–69. doi:10.1055/s-0035-1557893.
   PubMed Web of Science ®Google Scholar
• Olukoga A, Donaldson D. Liquorice and its health implications. J R Soc Promot Health. 2000;120(2):83–9. doi:10.1177/146642400012000203.
   PubMedGoogle Scholar
• Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am. 1994;23(2):359–77.
   PubMed Web of Science ®Google Scholar
• Hasegawa J, Suyama Y, Kinugawa T, Morisawa T, Kishimoto Y. Echocardiographic findings of the heart resembling dilated cardiomyopathy during hypokalemic myopathy due to licorice-induced pseudoaldosteronism. Cardiovasc Drugs Ther. 1998;12(6):599–600.
   PubMed Web of Science ®Google Scholar
• Husain I, Bala K, Khan IA, Khan SI. A review on phytochemicals, pharmacological activities, drug interactions, and associated toxicities of licorice (Glycyrrhiza sp.). Food Frontiers. 2021;2:449–485. doi:10.1002/fft2.110.
   Google Scholar
• Winter G. FDA warns food companies about herbal additives. The New York Times. 2001; C1–17.
   Google Scholar
• Heikens J, Fliers E, Endert E, Ackermans M, van Montfrans G . Liquorice-induced hypertension—a new understanding of an old disease: case report and brief review. Neth J Med. 1995;47(5):230–4. doi:10.1016/0300-2977(95)00015-5.
   PubMed Web of Science ®Google Scholar
• de Klerk GJ, Nieuwenhuis MG, Beutler JJ. Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum. BMJ. 1997;314(7082):731–2. doi:10.1136/bmj.314.7082.731.
   PubMed Web of Science ®Google Scholar
• Sigurjonsdottir H, Ragnarsson J, Franzson L, Sigurdsson G. Is blood pressure commonly raised by moderate consumption of liquorice? J Hum Hypertens. 1995;9(5):345–8.
   PubMed Web of Science ®Google Scholar
• Kent UM, Aviram M, Rosenblat M, Hollenberg PF. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450s 3A4, 2B6, and 2C9. Drug Metab Dispos. 2002;30(6):709–15. doi:10.1124/dmd.30.6.709.
   PubMed Web of Science ®Google Scholar
• Haron MH, Avula, B, Gurley, BJ, Chittiboyina, AG, Khan, IA, Khan, SI. Possible herb-drug interaction risk of some nutritional and beauty supplements on antiretroviral therapy in HIV patients. J Dietary Suppl. 2022;19(1):62–77. doi:10.1080/19390211.2020.1846658.
   PubMed Web of Science ®Google Scholar
• Manda VK, Avula B, Dale OR, Ali Z, Khan IA, Walker LA, Khan SI . PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids . Phytother Res. 2017;31(12):1935–45. doi:10.1002/ptr.5942.
   PubMed Web of Science ®Google Scholar
• Husain I, Manda V, Alhusban M, Dale OR, Bae J-Y, Avula B, Gurley BJ, Chittiboyina AG, Khan IA, Khan SI, et al. Modulation of CYP3A4 and CYP2C9 activity by Bulbine natalensis and its constituents: an assessment of HDI risk of B. natalensis containing supplements. Phytomedicine. 2021;81:153416. doi:10.1016/j.phymed.2020.153416.
   PubMed Web of Science ®Google Scholar
• Husain I, Dale OR, Manda V, Ali Z, Gurley BJ, Chittiboyina AG, Khan IA, Khan SI. Bulbine natalensis (currently Bulbine latifolia) and select bulbine knipholones modulate the activity of AhR, CYP1A2, CYP2B6, and P-gp. Planta Med. 2021. doi:10.1055/a-1557-2113.
   Web of Science ®Google Scholar
• Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl)). 2011;3:35–44. doi:10.2147/HIV.S14559.
   PubMedGoogle Scholar
• Mehta R, Wolstenholme A, Di Lullo K, Fu C, Joshi S, Crauwels H, Givens N, Vanveggel S, Wynne B, Adkison K, et al. Bioequivalence of a fixed-dose combination tablet of the complete two-drug regimen of dolutegravir and rilpivirine for treatment of HIV-1 infection. Antimicrob Agents Chemother. 2018;62(9):e00748-18. doi:10.1128/AAC.00748-18.
   PubMed Web of Science ®Google Scholar
• Nguyen B, Foisy MM, Hughes CA. Pharmacokinetics and safety of the integrase inhibitors elvitegravir and dolutegravir in pregnant women with HIV. Ann Pharmacother. 2019;53(8):833–44. doi:10.1177/1060028019830788.
   PubMed Web of Science ®Google Scholar
• Fenwick G, Lutomski J, Nieman C. Liquorice, Glycyrrhiza glabra L.—Composition, uses and analysis. Food Chem. 1990;38(2):119–43. doi:10.1016/0308-8146(90)90159-2.
   Web of Science ®Google Scholar
• Kao T-C, Wu C-H, Yen G-C. Bioactivity and potential health benefits of licorice. J Agric Food Chem. 2014;62(3):542–53. doi:10.1021/jf404939f.
   PubMed Web of Science ®Google Scholar
• Fiore C, Eisenhut M, Ragazzi E, Zanchin G, Armanini D. A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol. 2005;99(3):317–24. doi:10.1016/j.jep.2005.04.015.
   PubMed Web of Science ®Google Scholar
• Isbrucker R, Burdock G. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol. 2006;46(3):167–92. doi:10.1016/j.yrtph.2006.06.002.
   PubMed Web of Science ®Google Scholar
• Allcock E, Cowdery J. Hypertension induced by liquorice tea. Case Rep. 2015;2015(jun15 1):bcr2015209926. doi:10.1136/bcr-2015-209926.
   Google Scholar
• NCCIH. Licorice root, August 2020; [accessed 12 November 2020]. http://nccih.nih.gov/health/licoriceroot.
   Google Scholar
• Deutch MR, Grimm D, Wehland M, Infanger M, Krüger M. Bioactive candy: effects of licorice on the cardiovascular system. Foods. 2019;8(10):495. doi:10.3390/foods8100495.
   Web of Science ®Google Scholar
• Sabbadin C, Bordin L, Donà G, Manso J, Avruscio G, Armanini D. Licorice: from pseudohyperaldosteronism to therapeutic uses. Front Endocrinol (Lausanne)). 2019;10:484. doi:10.3389/fendo.2019.00484.
   PubMed Web of Science ®Google Scholar
• Volqvartz T, Vestergaard AL, Aagaard SK, Andreasen MF, Lesnikova I, Uldbjerg N, Larsen A, Bor P. Use of alternative medicine, ginger and licorice among Danish pregnant women—a prospective cohort study. BMC Complement Altern Med. 2019;19(1):5. doi:10.1186/s12906-018-2419-y.
   PubMedGoogle Scholar
• Bailly C, Vergoten G. Glycyrrhizin: an alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol Ther. 2020;214:107618. doi:10.1016/j.pharmthera.2020.107618.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Hiraoka N, Ikeshiro Y, Yamamoto H. Organ specific localization of flavonoids in Glycyrrhiza glabra L. Plant Sci. 1996;116(2):233–8. doi:10.1016/0168-9452(96)04387-7.
   Web of Science ®Google Scholar
• Hayashi H, Hattori S, Inoue K, Khodzhimatov O, Ashurmetov O, Ito M, Honda G. Field survey of Glycyrrhiza plants in Central Asia (3). Chemical characterization of G. glabra collected in Uzbekistan. Chem Pharm Bull (Tokyo)). 2003;51(11):1338–40. doi:10.1248/cpb.51.1338.
   PubMed Web of Science ®Google Scholar
• Kondo K, Shiba M, Nakamura R, Morota T, Shoyama Y. Constituent properties of licorices derived from Glycyrrhiza uralensis, G. glabra, or G. inflata identified by genetic information. Biol Pharm Bull. 2007;30(7):1271–7. doi:10.1248/bpb.30.1271.
   PubMed Web of Science ®Google Scholar
• Simmler C, Pauli GF, Chen S-N. Phytochemistry and biological properties of glabridin. Fitoterapia. 2013;90:160–84. doi:10.1016/j.fitote.2013.07.003.
   PubMed Web of Science ®Google Scholar
• Pal D, Kwatra D, Minocha M, Paturi DK, Budda B, Mitra AK . Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci. 2011;88(21-22):959–71. doi:10.1016/j.lfs.2010.09.012.
   PubMed Web of Science ®Google Scholar
• Pal D, Mitra AK . MDR- and CYP3A4-mediated drug-drug interactions . J Neuroimmune Pharmacol. 2006;1(3):323–39. doi:10.1007/s11481-006-9034-2.
   PubMed Web of Science ®Google Scholar
• Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol. 2007;3(4):583–98. doi:10.1517/17425255.3.4.583.
   PubMed Web of Science ®Google Scholar
• Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL . Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist. J Pharmacol Exp Ther. 2010;332(2):562–8. doi:10.1124/jpet.109.161893.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos. 2011;39(7):1139–48. doi:10.1124/dmd.111.038067.
   PubMed Web of Science ®Google Scholar
• Ueda R, Iketaki H, Nagata K, Kimura S, Gonzalez FJ, Kusano K, Yoshimura T, Yamazoe Y. A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol. 2006;69(6):1924–30. doi:10.1124/mol.105.021220.
   PubMed Web of Science ®Google Scholar
• Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem. 2004;279(23):23847–50. doi:10.1074/jbc.R400004200.
   PubMed Web of Science ®Google Scholar
• Gao YD, Olson SH, Balkovec JM, Zhu Y, Royo I, Yabut J, Evers R, Tan EY, Tang W, Hartley DP, et al. Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica. 2007;37(2):124–38. doi:10.1080/00498250601050412.
   PubMed Web of Science ®Google Scholar
• Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos. 2009;37(8):1611–21. doi:10.1124/dmd.109.027565.
   PubMed Web of Science ®Google Scholar
• Delfosse V, Dendele B, Huet T, Grimaldi M, Boulahtouf A, Gerbal-Chaloin S, Beucher B, Roecklin D, Muller C, Rahmani R, et al. Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds. Nat Commun. 2015;6(1):1–10. doi:10.1038/ncomms9089.
   Google Scholar
• Wang X, Zhang H, Chen L, Shan L, Fan G, Gao X . Liquorice, a unique “guide drug” of traditional Chinese medicine: a review of its role in drug interactions. J Ethnopharmacol. 2013;150(3):781–90. doi:10.1016/j.jep.2013.09.055.
   PubMed Web of Science ®Google Scholar
• Tsukamoto S, Aburatani M, Yoshida T, Yamashita Y, El-Beih AA, Ohta T. CYP3A4 inhibitors isolated from licorice. Biol Pharm Bull. 2005;28(10):2000–2. doi:10.1248/bpb.28.2000.
   PubMed Web of Science ®Google Scholar
• Lv Q-L, Wang G-H, Chen S-H, Hu L, Zhang X, Ying G, Qin C-Z, Zhou H-H. In vitro and in vivo inhibitory effects of glycyrrhetinic acid in mice and human cytochrome P450 3A4. Int J Environ Res Public Health. 2016;13(1):84. doi:10.3390/ijerph13010084.
   Web of Science ®Google Scholar
• Meyer R. Pseudohyperaldosteronismus-Lakritzverzehr mit Folgen. Deutsches Arzteblatt-Arztliche Mitteilungen-Ausgabe A. 2000;97(10):596–7.
   Google Scholar
• Feierman DE, Melinkov Z, Nanji AA. Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcoholism Clin Exp Res. 2003;27(6):981–8. doi:10.1111/j.1530-0277.2003.tb04424.x.
   PubMed Web of Science ®Google Scholar